NEW HAVEN, Conn.--(BUSINESS WIRE)--Kolltan Pharmaceuticals, Inc., a privately held clinical-stage company focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases, today announced key oral and poster presentations related to its lead development programs at upcoming conferences. An abstract on the Company’s anti-KIT monoclonal antibody drug candidate, KTN0158, has been chosen for oral presentation at the 30th Annual Society for Immunotherapy of Cancer (SITC) Conference, being held November 4- 8 in National Harbor, Maryland. Kolltan will also be presenting preclinical data on KTN0158 and KTN3379, its anti-ErbB3 monoclonal antibody drug candidate, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held November 5- 9 in Boston, Massachusetts.
Help employers find you! Check out all the jobs and post your resume.
